AG百家乐代理-红桃KAG百家乐娱乐城

Source: Sun Yat-sen University Cancer Center
Written by: Wang Zhao
Edited by: Wang Dongmei

The 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, the most important conference in the field of clinical oncology, ended with a series of breakthroughs in Chicago on June 4. Two clinical researches led by Professor Lin Tongyu from Sun Yat-Sen University Cancer Center, were chosen for special oral report. Professor Lin Tongyu and Dr Huang He were invited to introduce their work and show their achievements at this world-class arena in front of over 30,000 specialists.

Professor Lin Tongyu’s topic is about the treatment comparison for extranodal NK/T cell lymphoma, nasal type. He found that “CID-ATT” regimen is better than standard “CHOP” regimen, which suggests that non-cross resistant alternating regimen may be able to overcome drug resistance for a variety of other refractory malignancy treatment. Dr Huang He focused on the treatment for hepatitis B during tumor chemotherapy, and he recommended that entecavir should be the first choice rather than lamivudine for patients who suffered diffuse large B cell lymphoma with hepatitis B infection.

These two speeches are the only two oral reporting among hundreds of Chinese researches this year in ASCO, and this is the first time that two studies from one same study group were selected simultaneously in the same field. It is worth mentioning that one of them was selected as the “best research of ASCO”, which is also the first experience and great honor for Chinese researchers. Until now, only 6 Chinese specialists have given speeches in ASCO’s platform during its 49 years history, and three of them are from Sun Yat-sen University Cancer Center, indicating that the oncology studies at SYSU have been gradually reaching the international advanced level.